Spironolactone use and risk of incident cancers: a retrospective, matched cohort study

A high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug Spironolactone impairs cancer cell survival by inhibiting homology directed repair

(2014) Or David Shahar et al.   NUCLEIC ACIDS RESEARCH

Spironolactone use and the risk of breast and gynecologic cancers

(2013) Robert J. Biggar et al.   Cancer Epidemiology

Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation

(2013) Wai-Hang Leung et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Long-Term Survival of Participants in the Prostate Cancer Prevention Trial

(2013) Ian M. Thompson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study

(2012) I. S. Mackenzie et al.   BMJ-British Medical Journal

Validation and validity of diagnoses in the General Practice Research Database: a systematic review

(2009) Emily Herrett et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY